Parkinson’s Disease :: Boehringer Ingelheim’s pramipexole, mirapexin/sifrol to improve depressive and motivational symptoms

New data presented today from a meta-analysis* of nearly 1,300 Parkinson?s disease (PD) patients, indicate that pramipexole (Mirapexin?/Sifrol?) has a beneficial effect on depressive and motivational symptoms in PD.1 This confirms findings from previously published clinical trials,2,3,4 and is in addition to its established efficacy in controlling motor symptoms. These findings are of particular interest as mood symptoms in PD can affect up to 50 percent of the patient population.1,5 The data were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.

Hepatitis :: Glaxo eltrombopag improved platelet count in hepatitis C patients with thrombocytopenia

GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. In addition, 71% - 91% of patients in all treatment groups were able to initiate antiviral therapy with pegylated interferon-α (IFN) and ribavirin, and 65% were able to be maintained on therapy.1 Full results from this Phase II study are being presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts.

Cholesterol :: Patent Victory in Spanish Court Favoring Ranbaxy on Atorvastatin Unaffected

Ranbaxy Laboratories Limited said that recently, in two separate rulings, the Spanish courts (the Mercantile Court of Barcelona, No. 2) found Spanish patent ES 2,167,306 (counterpart of Pfizer’s EP 409 281) to be invalid for lack of novelty. The two rulings made on September 26, 2006, in Lek Pharmaceuticals v. Warner Lambert Co. and in Laboratorios Cinfa et al. v. Warner Lambert, found claims 1 to 3 of Pfizer to be invalid. These decisions came after considering the views of the Spanish Patent Office (SPO), in addition to technical expert reports.

Health Care :: Nursing Spectrum becomes Gannett Healthcare Group

Gannett Co., Inc. announced that Nursing Spectrum, a wholly owned subsidiary of Gannett since 1995 and the nation?s largest print and electronic publisher of information for registered nurses, is now Gannett Healthcare Group. The company?s 12 regional nursing publications will continue to operate under their existing brand names, Nursing Spectrum in the Eastern United States, and NurseWeek in the Western United States, as they have for nearly 20 years.

Nutrition :: Cognis launches 3 natural, non-GMO health ingredients at SupplySide West

Traffic at the Cognis Nutrition & Health booth at the SupplySide West trade show is expected to be brisk as dietary supplement and functional food manufacturers discover the benefits of three new, non-GMO natural health ingredients Cognis is launching — Covi-ox? T-95 EU natural mixed tocopherols, Vegapure? F40 WDP E water dispersible natural plant sterols, Xangold? 20% natural lutein ester beadlets.

Weight Loss :: Supplements help avoid ‘Weight Creep’ from Turkey and Sugar Plums – Tonalin CLA Study

CLA may serve critical role in preventing weight and fat gain during year-end holidays and with normal aging. Avoiding ‘weight creep’ from turkey and sugar plums is the theme of a consumer PR campaign Cognis Nutrition & Health is rolling out in time for the holiday season based on a Tonalin? CLA study recently published online in the prestigious International Journal of Obesity. The research suggests that Tonalin? CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.

Flu :: Cognis Targets Cold, Flu Season with Arsenal of Immunity-Enhancing Ingredients

A compromised immune system makes people more prone to contracting a cold or flu, and Cognis is helping companies meet the growing demand worldwide for immunity boosting dietary supplements and functional foods. Colds and flu are the most frequent infections across all age groups. Each year, Americans suffer from one billion colds, 100,000 are hospitalized and about 36,000 die from the flu and its complications. Immune health is also a global concern with frequent colds and flu ranked as one of the top three health problems by consumers in China, India and Latin America.

Nutrition :: Cognis to launch Omevital, omega-3 fatty acids at HiE

Cognis will unveil its new range of high quality omega-3 fish oil products at this year?s Health Ingredients Europe event in Frankfurt. Under the brand name Omevital?, and available in ethyl ester and triglyceride forms, the new range of marine-origin oils delivers products of outstanding quality and purity, ultra-refined through state-of-the-art manufacturing processes, in accordance with Pharma GMP standards.

Health :: Investigation of the physical and psychological health of UK Armed Forces

The King’s Centre for Military Health Research (KCMHR) has received further funding from the UK Ministry of Defence to continue its research into the health and well-being of military personnel, many of whom have served in Iraq. The research, which began in 2003 as a prospective investigation of the physical and psychological health of over 12,000 UK service personnel serving in Iraq, will be monitoring service personnel more widely, including those deployed to Afghanistan.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack